Target intelligence / Profile preview

SATB2 antisense RNA 1 (non-protein coding) (SATB2-AS1)

Target
SATB2-AS1
Molecular classification
Long non-coding RNA (lncRNA), Other
01

Overview

SATB2 antisense RNA 1 (SATB2-AS1) is a long non-coding RNA predominantly expressed in colorectal tissue, and also present in brain tissue. It is typically downregulated in colorectal cancer and glioma compared to healthy tissue. SATB2-AS1 regulates the expression of the SATB2 gene (Special AT-rich binding protein 2) by acting as a scaffold for chromatin-modifying proteins, promoting histone modification and DNA demethylation at the SATB2 promoter. Functionally, SATB2-AS1 inhibits tumor cell metastasis, modulates immune cell infiltration and immune gene expression, inhibits glycolysis, suppresses cell proliferation, and promotes apoptosis in cancer cells. In glioma, it also acts as a microRNA sponge, particularly for miR-671-5p, modulating downstream gene expression. Reduced SATB2-AS1 expression is linked to more aggressive disease and poorer prognosis in both colorectal cancer and glioma, suggesting its role as a tumor suppressor and a potential prognostic biomarker[1][3][4].

Other names
SATB2-AS1SATB2 antisense RNA 1SATB2 antisense RNA 1 (non-protein coding)
02

Mechanism of action

Acts as a molecular scaffold, recruiting chromatin-modulating proteins (WDR5 and GADD45A) to promote histone H3K4 methylation and DNA demethylation at the SATB2 promoter, thus activating SATB2 transcription (in cis) in colorectal cancer. Functions as a microRNA sponge (notably for miR-671-5p), thereby regulating targets such as CDR1 and VSNL1 in glioma.

03

Biological functions

Regulation of gene expression (specifically SATB2, a chromatin regulator)Inhibition of tumor metastasisRegulation of immune responseRegulation of cell metabolism (glycolysis)Modulation of apoptosis and cell proliferation
04

Disease associations

Cancer (colorectal cancer, glioma, glioblastoma)
05

Safety considerations

No direct safety concerns reported; as a non-coding RNA therapeutic target, delivery and specificity may be technical challenges
06

Interacting drugs

None directly identified in current literature
07

Biomarkers

Low expression in tumors (colorectal cancer, glioma) is associated with poor prognosis and increased metastasis risk; may serve as a prognostic biomarker in these cancers

Beyond the preview

Go deeper on SATB2 antisense RNA 1 (non-protein coding) (SATB2-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SATB2 antisense RNA 1 (non-protein coding) (SATB2-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call